Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...

Alpelisib is an orally bioavailable, α-selective PI3K inhibitor and degrader that showed efficacy and a manageable safety profile in combination with fulvestrant in the phase 3 SOLAR-1 study of ...

In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosteroneNo FDA-approved oral therapies currently exist for this un ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...

Research led by Samsung Medical Center finds breast cancer survivors exhibit an 8% lower risk of Alzheimer's dementia (AD) ...

Cite this: Cognitive Dysfunction in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors - Medscape - Aug 01, 2011.

Future study designs evaluating cognitive dysfunction in patients on aromatase inhibitors should include a multifaceted approach of neuropsychiatric testing and neurological functional imaging.